Kornimate/medical-research-clean huggingface dataset:
a study comparing upadacitinib (abt-494) to placebo in participants with active psoriatic arthritis who have a history of inadequate response to at least one biologic disease modifying anti-rheumatic drug

Conditions: Psoriatic Arthritis

Summary: this is a phase 3 multicenter study that includes two periods. period 1 is designed to compare the safety, tolerability, and efficacy of abt-494 dose a once daily (qd) and dose b qd versus placebo in participants with moderately to severely active psoriatic arthritis (psa) who have an inadequate response to biological disease modifying anti-rheumatic drug (bdmards). period 2 evaluates the safety, tolerability and efficacy of abt-494 dose a qd and dose b qd in subjects with psa who have completed period 1.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of psa with symptom onset at least 6 months prior to the screening visit and fulfillment of the classification criteria for psa (caspar) criteria * participant has active disease at baseline defined as \>= 3 tender joints (based on 68 joint counts) and \>= 3 swollen joints (based on 66 joint counts) at screening and baseline visits * diagnosis of active plaque psoriasis or documented history of plaque psoriasis * participant has had an inadequate response (lack of efficacy after a minimum 12 week duration of therapy) or intolerance to treatment with at least 1 bdmard. exclusion criteria: * prior exposure to any janus kinase (jak) inhibitor (including but not limited to ruxolitinib, tofacitinib, baricitinib, and filgotinib) * current treatment with \> 2 non-biologic dmards or use of dmards other than methotrexate (mtx), sulfasalazine (ssz), leflunomide (lef), apremilast, hydroxychloroquine (hcq), bucillamine or iguratimod or use of mtx in combination with lef at baseline. * history of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than psa (including, but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus). prior history of reactive arthritis or axial spondyloarthritis including ankylosing spondylitis and non-radiographic axial spondyloarthritis is permitted if documentation of change in diagnosis to psa or additional diagnosis of psa is made. prior history of fibromyalgia is permitted if documentation of change in diagnosis to psa or documentation that the diagnosis of fibromyalgia was made incorrectly.

Keywords: arthritis psoriasis anti-rheumatic anti-inflammatory joint disease musculoskeletal disease
clinical application of circulating tumor dna (ctdna) in patients with late-stage breast cancer

Conditions: Metastatic Breast Cancer; Circulating Tumor DNA; Gene Abnormality

Summary: this is a retrospective, observational, multi-center clinical study of circulating tumor dna (ctdna) application in late-stage breast cancers.

this study aims to evaluate the feasibility of plasma ctdna mutation spectrum and clonal spectrum in late-stage metastatic breast cancer patients. meanwhile, this study tries to establish a model of ctdna subtyping system to evaluate the molecular load of tumor, to evaluate the curative effect comprehensively and to detect the disease progression in advance. in addition, the investigators plan to explore the clonal evolution of ctdna in patients with progressive disease (pd), and to monitor the changes of tumor heterogeneity from the molecular level, so as to provide reference for the analysis of drug sensitivity.

Eligibility criteria:
inclusion criteria: * recent progression of tnbc after multiple lines of chemotherapy or of hr+ or her2+ mbc after multiple lines of endocrine or targeted therapy; * no available recommendation for the next treatment regimen; * an eastern cooperative oncology group (ecog) performance status of 0 to 2; * an updated, available pathological hr/her2 status for metastasis; * according to recist 1.1 standard, there should be at least one measurable target lesion; * the expected survival time is \> 3 months; * those aged 18-70 years old; * liver and kidney function and blood routine test meet the following conditions: neutrophil \> 2.0g/l, hb \> 9g / l, plt \> 100g / l; alt and ast \< 2.5uln; tbil \< 1.5uln; cr \< 1.0uln * signing informed consent; * those willing to accept polygenic testing. exclusion criteria: * patients with multiple primary tumors; * those who are unable to obtain blood samples; * those with a history of immunodeficiency or organ transplantation; * those with abnormal cardiac function or previous history of myocardial infarction or serious arrhythmia; * the researchers think it is not suitable to participate in this experiment.
effect of myofascial release on dysphagia prevention for elderly people in the community

Conditions: Dysphagia

Summary: the goal of this clinical trial is to explore the impact of myofascial release training on swallowing function and quality of life in community-dwelling elderly individuals (≥60 year old) with swallowing disorders. it primarily aims to address the effects of myofascial release training on swallowing function and quality of life in community-dwelling elderly individuals with swallowing disorders. all participants are required to undergo a continuous three-week (21 days) myofascial release training, with weekends off and training conducted only on weekdays. the training will be conducted two sessions per day, lasting 15-30 minutes each.

myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. it involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. the goal of this clinical trial is to explore the impact of myofascial release training on swallowing function and quality of life in community-dwelling elderly individuals (≥60 year old) with swallowing disorders. it primarily aims to address the effects of myofascial release training on swallowing function and quality of life in community-dwelling elderly individuals with swallowing disorders. all participants are required to undergo a continuous three-week (21 days) myofascial release training, with weekends off and training conducted only on weekdays. the training will be conducted two sessions per day, lasting 15-30 minutes each.

Eligibility criteria:
inclusion criteria: * age over 60 years old. * no hospitalization within the past six months. * with clear consciousness and able to cooperate with questionnaires and training. * the elderly people who voluntarily participate and agree to adhere until the end of the study. * dysphagia exclusion criteria: * complicated with severe liver and kidney failure, tumors, or hematological disorders. * physical disability. * difficulty in mobility.
a study to evaluate animal-assisted therapy in stroke rehabilitation

Conditions: Stroke

Summary: the investigators hypothesize that the presence of a mayo clinic certified therapy dog will provide additional benefits above typical treatment for patients currently enrolled in the mayo clinic stroke rehabilitation unit.

the objectives of this study are to measure the effects of a therapy dog embedded in stroke rehabilitation sessions on the patients' functional recovery, depression, anxiety, motivation, and quality of life.

Eligibility criteria:
inclusion criteria: * patient must be 18 years of age or older. * patient must be in the comprehensive in-patient stroke rehabilitation program. * patient must have a stroke from any cause. * patients must be able and willing to give informed consent. * patients must be able to speak english as the questionnaires being used are only available in english. exclusion criteria: * patient who has a pacemaker. * patient who is pregnant. * patient who is deemed inappropriate to the study by the medical professional. * patient who is unable to give informed consent. * patient who is unable to speak english.
adult arm of dzl all age asthma cohort (alliance)

Conditions: Asthma

Summary: deep phenotyping of adult asthma patients: * severity from mild to severe * both atopic and non-atopic * both childhood and adult onset * both smokers and non-smokers * corresponding pediatric cohort (pediatric arm of dzl all age asthma cohort) with equivalent sops regarding collection of biomaterial and clinical data incl. lung function, further processing of biomaterial and further analyses

the clinical heterogeneity of asthma patients has been increasingly recognised within the last years. recent studies and articles highlighted the idea of asthma not beeing a single disease but rather a unifying term for multiple phenotypes. phenotype in this sense is defined as the combination of observable properties of an organism, that are produced by the interactions of a genotype and the environment. in contrast, endotype describes a specific underlying pathophysiological pathway. linking asthma phenotypes and endotypes in a system biological approach is an important research goal in order to develop targeted therapy, especially for severe asthma. the advantage the investigators' cohort provides is the collaboration with an equivalent pediatric cohort. in this setting questions regarding disease onset, exacerbation and chronicity can be posed and worked with in a comprehensive manner.

Eligibility criteria:
inclusion criteria: * proven diagnosis according to current gina guideline (2014) * ability to read and understand german * ability to understand and agree to informed consent exclusion criteria: * history of respiratory tract infection within the last 4 weeks before inclusion

Keywords: asthma phenotype childhood adulthood
recurrence of thromboembolic venous disease of atypical location (ruse)

Conditions: Venous Thromboembolism

Summary: ruse is a retrospective data-based study designed to assess the frequency, characteristics and phenotype of documented recurrences of thromboembolic venous disease in atypical locations.


Eligibility criteria:
inclusion criteria: * all patients over 18, * affiliated to "sécurité sociale" * having at least one episode of atypical localisation of vte at brest university hospital exclusion criteria: * patients under legal protection * minors * refusal to participate
human immunodeficiency virus (hiv)and chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: highly active antiretroviral therapy (haart) has considerably improved survival of hiv-infected patients. opportunist diseases and cancers linked to immunodepression have largely regressed. challenge is now the management of cardio-vascular diseases, nephrologic, neurologic, osteo-articular diseases, chronic hepatitis and cancer no linked to immunodepression. all this comorbidities are more reported in hiv-infected patients than in general non-hiv infected patients. those are directly linked to the effect of chronic hiv-infection on ageing, metabolic effects of haart, and way of life characterising this population. chronic obstructive pulmonary disease (copd) results from tobacco consumption. bronchial chronic infection, immunity, and ageing are also involved in the physiopathology of copd. this disease has never been evaluated in a large prospective cohort of hiv-infected patients whereas there is a known increase of tobacco consumption and pulmonary infection in this population regardless to the general population. characterisation of copd disease in hiv patients will allow us to make an hypothetic epidemiological link between hiv- haart and copd independently of tobacco consumption, and to study different physiopathologic hypothesis evocated in copd genesis, like an accelerate pulmonary ageing.

the management of hiv is mainly represented by its commorbidities (cardio-vascular disease, nephrologic, neurologic, osteo-articular disease, chronic hepatitis and cancer no linked to immunodepression). copd prevalence has never been studied in hiv population. in consequence, there is no guideline about the screening, treatment or follow-up of copd in hiv patients. however this population seems particularly at risk to develop copd because of high tobacco consumption and accelerate ageing. thus, we need an epidemiologic study to understand the prevalence of copd in hiv population in order to organize a specific screening and follow-up. this is supported by an improvement of copd if early managed. on top of that, copd screening will increase awareness of hiv patients on the problematic of tobacco consumption.

Eligibility criteria:
inclusion criteria: * hiv seropositivity * age \> 18 years * written aggreeing * affiliated or profit of a social coverage non inclusion criteria: * age \< 18 years old * actual infectious pneumonia * copd exacerbation last 2 months \* * recent (less than 1 month) myocardial infarction * thoracic or abdominal pain * enable to answer question secondary to mental deficienty\*\* * physic or mental incapacity to realise copd-6 or spirometery * urinary incontinency with effort * prisoner * refuse of consent or incapacity to give his consent
assessment of cortical plasticity following short term limb immobility

Conditions: Fracture

Summary: the proposed project will study the consequence of short term limb immobility on the patterns of brain activity using functional imaging (fmri)


Eligibility criteria:
inclusion criteria: * wrist fracture. * fit for mri scanning. exclusion criteria: * unwillingness to sign informed consent. * neurological disease * s/p fractures
activated charcoal use in chronic kidney disease patients

Conditions: End Stage Renal Disease (ESRD); CKD 5D, Hemodialysis; CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder

Summary: hyperphosphatemia management is initially based on restricting dietary phosphorus intake. hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.


Eligibility criteria:
inclusion criteria: 1. adult aged ≥18 years with esrd. 2. patients who had been on stable maintenance hemodialysis (3 times weekly) for at least 6 months. 3. patients receiving phosphate binders according to standard protocols established by kidney disease: improving global outcomes (kdigo). exclusion criteria: 1. severely malnourished (as diagnosed by the department's dietitian). 2. treated with overnight dialysis. 3. primary hyperparathyroidism or persistent serum levels of intact parathyroid hormone greater than 800 pg/ml.
analgesic protocol with gabapentin dexmedetomidine for postoperative pain managment

Conditions: Analgesia

Summary: assessment of quality of post mastectomy analgesic protocol of gabapentin and dexmedetomedine in a placebo-controlled study

assessment of quality of post mastectomy analgesic protocol of gabapentin and dexmedetomedine in a placebo-controlled study. dexmedetomidine is a highly selective x2 adrenergic receptor aganist; it has anxiolytic, sedative, analgesic and sympathdytic properties without significant respiratory depressant effects. research evidence has shown that this drug protects the body (including heart, nerves, etc.) against ischemia and hypoxic injury. therefore, dexmedetomidine can be one of the best options for reducing pain after surgery. gabapentin, a structural analog of gamma aminobutyric acid, is used as an anticonvulsant drug since 1993. in addition it has been effective in neuropathic pain, diabetic neuropathy and reflex sympathetic dystrophy. it acts through binding to the x-2-5 subvnits of voltagegated calcium ion channels and preventing the central sentization and hyperalgesia. gabapentin has demonstrated to inhibit the development and establishment of hyperalgesia and secondry allodynia in human volunteers. gabapentin may also decrease postoperative obioid requirement through preventing the tolerance development. furthermore, it has minimal or no effect on gastric mucosa, renal function, and platelets count or activity in the perioperative period to be prefer over nonsteroidal anti-inflammatory drugs. the combination of both drugs will be tested for potentiation of post-operative analgesia and decrease of opioid consumptions

Eligibility criteria:
inclusion criteria: * adult female patients below 65 years of age scheduled for modified radical mastectomy surgery, american society of anesthesiologists(asa) physical status i-ii exclusion criteria: * known allergy to study drugs; patients already taking oral gabapentin, knal or hepatic defunction, current treatment with narcotics, antihypertensives, benzodiazepines, x2 agonists, antiepileptics and antipsychotics
sleep disturbances as a non-traditional risk factor in ckd-actigraphy

Conditions: Chronic Kidney Disease; Sleep Loss

Summary: to test if usual at home night time sleep duration as measured with activity monitors and questionnaires will predict changes in kidney function as measured by kidney filtration rate and of cardiovascular function as measured by c-reactive protein in the blood. the study will explore the role of decreased sleep time or decreased sleep quality as a non-traditional risk factor for the progression of ckd and for the development of cardiovascular disease in ckd.


Eligibility criteria:
inclusion criteria: * mild to moderate ckd * healthy controls age and gender matched to ckd subjects * regular bedtimes of at least 6h/night, sedentary lifestyle exclusion criteria: * diabetes * current or previous dialysis for more than 1 month * uncontrolled hypertension * heart failure * liver disease * hiv * hemoglobin \< 10.5 g/dl * treatment with eprocrit, epogen, or aranesp * bone or organ transplant, * use of immunosuppressive drugs within past 6 months * current oral contraceptive use * current pregnancy * chemotherapy for malignancy within past 2 years

Keywords: ckd kidney disease poor sleep ckd progression
retrospective observational cohort study of symbol cup dm 1

Conditions: Primary Total Hip Arthroplasty

Summary: this is a single-center retrospective observational cohort study of consecutively operated patients who underwent primary total hip arthroplasty with a symbol cup dm ha hemispherical dual mobility acetabular implant. the purpose of this study is to estimate the safety and efficacy of that implant at two-year follow-up.

description according to picos framework: patients: - adult men and women requiring a primary total hip arthroplasty intervention: - primary tha with symbol cup dm ha hemispherical dual mobility acetabular implant. comparator: none outcomes: * safety 1: implant survival over 2-year follow-up. * safety 2: all adverse events, with focus on implant dislocation, infections, revision surgery * efficacy 1: harris hip score (hhs) at baseline and 1-year follow-up. * efficacy 2: modified hhs consisting of pain + functional subscores at baseline, 1-year and 2-year follow-ups. * efficacy 2: devane score at baseline, 1-year and 2-year follow-ups. * efficacy 3: charnley classification at baseline, 1-year and 2-year follow-ups. study design: * single-center retrospective observational cohort study of consecutively operated patients who underwent primary total hip arthroplasty 2 years prior to study start. * prospective 2-year follow-up letter and phone questionnaire.

Eligibility criteria:
inclusion criteria: * all patients with total hip implant using hemispheric dual-mobility symbol cup dm ha * operation performed by the primary investigator * delay between index operation and march 1 2018 has reached 2 years exclusion criteria: * patient refusal to participate in the study * minors (age \< 18 years) * patients under guardianship

Keywords: primary total hip arthroplasty hemispherical dual-mobility acetabular cup safety efficacy implant survival prosthetic dislocation harris hip score hhs
a case control study of the prevalence of pulmonary hypertension in patients with myeloproliferative diseases.

Conditions: Myeloproliferative Disease; Pulmonary Hypertension

Summary: pulmonary hypertension (ph) is defined as a group of diseases characterised by an elevated mean pulmonary artery pressure (ppa) ≥25 mmhg at rest. recently, chronic myeloproliferative diseases (cmpd) associated with pulmonary hypertension were included in the group 5 category, corresponding to ph for which the aetiology is unclear and/or multifactorial. cmpd include chronic myelogenous leukaemia, chronic neutrophilic leukaemia and chronic eosinophilic leukaemia (which primarily express a myeloid phenotype and polycythaemia vera), idiopathic myelofibrosis, and essential thrombocytosis in which erythroid or megakaryocytic hyperplasia predominates. the purpose of this research: 1. assess prevalence of ph in patients with cmpd in northern israel 2. describe the demographics and clinical course in patients with cmpd who are diagnosed with ph.

study will include the following: * sex * age * bmi * ethnicity * age diagnosed with myeloproliferative disease * clinical manifestations of the myeloproliferative disease * jak2 mutation * known hematological complications

Eligibility criteria:
inclusion criteria: 1) consenting patients diagnosed with a myeloproliferative disease exclusion criteria: 1) refusal to have an echocardiogram or answer the st. george respiratory questionnaire

Keywords: myeloproliferative disease pulmonary hypertension
genetic susceptibility for bronchopulmonary dysplasia in preterm infants

Conditions: Bronchopulmonary Dysplasia

Summary: despite considerable obstetric and neonatal advances in the care of very low birth weight (vlbw) neonates, bronchopulmonary dysplasia (bpd) continues to occur among 20 to 40% of surviving infants, and new ways for combatting this disease must be found. bpd appears to result from arrested lung development, but its etiology has not yet been fully established. besides the role of the exposure of the immature lung to injurious factors in the development of bpd, a genetic susceptibility for bpd in preterm infants was recently evidenced. taking advantage of new genomic technologies, the objective of the investigators' project is to identify predisposing human genetic variants through: 1. a genome-wide association (gwa) study in vlbw neonates, 2. a candidate-gene association study, including selection of single nucleotide polymorphisms (snps) found in (a) and 3. functional studies of any snp found to be convincingly associated with bpd in (a) and (b).


Eligibility criteria:
inclusion criteria: * gestational age \< 28 weeks * inborn birth * prophylactic administration of surfactant in the delivery room * written informed consent obtained from parents exclusion criteria: * gestational age of 28 weeks or more * outborn birth * no prophylactic administration of surfactant in the delivery room * congenital malformation * absence of written informed consent obtained from parents

Keywords: bronchopulmonary dysplasia neonates lung development prematurity